P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

Bibliographic Details
Main Authors:	V. Pullarkat, A. Cruz-Chacon, S. Gangatharan, A. Melnyk, G. A. Palumbo, M. Bellini, S. K. Tantravahi, Q. Qin, J. Potluri, P. Vachhani
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847148.78233.c8

Similar Items

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
by: F. Passamonti, et al.
Published: (2022-06-01)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
by: John Mascarenhas, et al.
Published: (2023-08-01)

Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates
by: Edward F. Greenberg, et al.
Published: (2024-08-01)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
by: P. Abraham, et al.
Published: (2022-06-01)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
by: Claire Harrison
Published: (2015-04-01)

Treatment and management of myelofibrosis in the era of JAK inhibitors
by: Keohane C, et al.
Published: (2013-08-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2021-08-01)

External migration of the Finns in the 1070's
by: Altti Majava
Published: (1977-01-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
by: Prithviraj Bose, et al.
Published: (2020-08-01)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
by: Keohane C, et al.
Published: (2013-10-01)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
by: Haris Ali, et al.
Published: (2023-08-01)

Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
by: Nur Najmi Mohamad Anuar, et al.
Published: (2020-11-01)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
by: Reilly, J, et al.
Published: (2014)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
by: Reilly, J, et al.
Published: (2014)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
by: Jui‐Che Chen, et al.
Published: (2022-02-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
by: V. Gupta, et al.
Published: (2022-06-01)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
by: Derek W. Brown, et al.
Published: (2022-09-01)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01)

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
by: S. Verstovsek, et al.
Published: (2022-06-01)

Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic
by: Ana C. Henriques, et al.
Published: (2021-02-01)

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
by: Leopoldo Sitia, et al.
Published: (2021-02-01)

Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis
by: Sebastian Francis, et al.
Published: (2024-04-01)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
by: A. Vannucchi, et al.
Published: (2022-06-01)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
by: Christopher Gerard Mullen, et al.
Published: (2022-11-01)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
by: Douglas Tremblay, et al.
Published: (2023-06-01)

Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
by: Ayesha Gul, et al.
Published: (2022-06-01)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
by: Martina Barone, et al.
Published: (2020-01-01)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
by: Marte Karen Brattås, et al.
Published: (2018-11-01)

Rev. Saúde Pública 2007;41(6):1070
Published: (2008-04-01)

Preparation of high-purity cyclodextrin glucanotransferase from Bacillus sp. 1070 /
by: Volkova, D.A.

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
by: Sophia S. Lee, et al.
Published: (2021-08-01)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
by: Leonardo Caires dos Santos, et al.
Published: (2011-12-01)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
by: Sousos, N, et al.
Published: (2020)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
by: Abrar Softah, et al.
Published: (2023-11-01)

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
by: Jay Y. Spiegel, et al.
Published: (2017-09-01)

Phase equilibria in the Gd–Cr–Ge system at 1070 K
by: M. Konyk, et al.
Published: (2021-05-01)

Temporally Stable Random Fiber Laser Operates at 1070 nm
by: Xueyuan Du, et al.
Published: (2015-01-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2023-03-01)